What Is Sexual Wellness?
Sexual wellness covers the products, services, and healthcare that support a person’s sexual and reproductive health, from contraception and STI testing to sexual health supplements, lubricants, and consultations with a doctor. It sits at the intersection of consumer retail and public health, which is exactly why it looks so different depending on which side you’re measuring: one half of the picture is a fast-growing commercial market selling products online and in pharmacies, and the other half is the NHS-run public health system tracking infections, funding local clinics, and rolling out new testing technology.
In the United Kingdom in 2026, both halves of that picture are shifting at once. Telehealth has become the default way many people access STI testing and sexual health consultations, replacing a clinic visit with a kit that arrives by post or a video call with a prescriber. At the same time, official diagnosis data shows genuine, measurable improvement in several major infections, even as funding for the public health services that make testing possible has fallen in real terms over the past decade. This guide brings together the latest verified data on the UK’s sexual wellness market, telehealth and online testing adoption, STI diagnosis trends, and NHS sexual health service capacity.
Interesting Facts About Sexual Wellness in the UK 2026
Sexual Wellness in the UK, 2026
UK sexual wellness market size, 2024 |███████████████ $6.58B
STI diagnoses in England, YoY change, 2025 |▼ -8.3%
Chlamydia testing via online kits, 2022 |█████████████ 38.4%
Chlamydia testing via online kits, 2015 |███ 2.6%
| Interesting Fact | Figure |
|---|---|
| UK sexual wellness market size, 2024 | $6.58 billion |
| UK share of the European sexual wellness market, 2025 | 18.6% (2nd largest) |
| Overall STI diagnoses in England, change in 2025 | -8.3% |
| Chlamydia diagnoses, share of all new STIs in 2025 | 45.2% |
| Chlamydia testing completed via online postal kits, 2022 vs. 2015 | 38.4% vs. 2.6% |
| Local authority sexual health service spending, 2013/14 vs. 2024/25 | £859m vs. £586m |
| Infectious syphilis diagnoses among GBMSM, 2025 change | -18.7% (lowest since 2016) |
| European telehealth use for sensitive health issues, growth 2020-2024 | +120% |
Source: MarketResearchFuture UK Sexual Wellness Market Report, 2026; UK Health Security Agency Annual STI Data, June 2026; House of Commons Library, June 2026.
The headline numbers show a system where commercial demand and public health capacity are moving in different directions. The UK’s sexual wellness market was worth $6.58 billion in 2024 and holds 18.6% of the entire European market, second only to Germany, driven largely by consumers shifting to online and telehealth channels. On the public health side, England recorded an 8.3% fall in overall STI diagnoses in 2025, with chlamydia remaining the single most common infection at 45.2% of all new diagnoses. That improvement arrives even as local authority sexual health service funding has fallen from £859 million in 2013/14 to £586 million in 2024/25 once inflation is accounted for, a real-terms cut of roughly a third over the same period that testing and telehealth infrastructure have had to work around.
Telehealth is the clearest thread connecting these numbers. The share of chlamydia testing completed through online postal self-sampling rose from just 2.6% of tests in 2015 to 38.4% by 2022, a shift that has let services process far more tests without a proportional increase in clinic funding or staff. Across Europe more broadly, telehealth consultations for sensitive health issues grew 120% between 2020 and 2024, and the UK has been at the front of that shift specifically because of its early, large-scale rollout of postal testing kits. The sections below break down each of these threads individually, using data drawn from the UK’s official STI surveillance system, peer-reviewed research on online testing adoption, and current market analysis.
UK Sexual Wellness Market Size Statistics in the UK 2026
UK Sexual Wellness Market Growth
2024 market value |█████████████ $6.58B
2035 projected value |████████████████████████ $15.55B
Annual growth rate (CAGR) 8.138%
| Market Metric | Figure |
|---|---|
| UK sexual wellness market size, 2024 | $6.58 billion |
| UK sexual wellness market size, projected 2035 | $15.55 billion |
| Compound annual growth rate, 2025-2035 | 8.138% |
| UK share of the European sexual wellness market, 2025 | 18.6% (2nd largest) |
| Online retail segment growth rate, Europe, 2026-2034 | 11.2% CAGR |
Source: MarketResearchFuture UK Sexual Wellness Market Report, 2026; Europe Sexual Wellness Market Report, MarketDataForecast, 2026.
The UK sexual wellness market was valued at $6.58 billion in 2024 and is projected to more than double to $15.55 billion by 2035, growing at a compound annual rate of 8.138%. That places the UK as the second-largest sexual wellness market in Europe, holding 18.6% of the regional total, behind only Germany. The growth is being driven overwhelmingly by what the industry calls channel shift: consumers moving away from browsing a pharmacy shelf and toward ordering discreetly online, whether that’s a subscription lubricant brand, a telehealth consultation for contraception, or a same-day-delivery STI test kit.
That channel shift is measurable at the category level too. Across Europe, the online retail segment of the sexual wellness market is projected to grow at 11.2% annually between 2026 and 2034, outpacing nearly every other distribution channel, a trend the industry attributes directly to the anonymity online ordering provides for a category many consumers still find sensitive to buy in person. For UK retailers and telehealth providers, the market data suggests the winners over the next decade will be less about any single product category and more about who builds the smoothest, most private path from browsing to delivery, since that discretion factor appears to matter more to UK shoppers than price alone.
Telehealth Adoption for Sexual Health Statistics in the UK 2026
Chlamydia Testing via Online Postal Self-Sampling, England
2015 |██ 2.6%
2020 (pandemic acceleration)|██████████████████ doubled YoY
2022 |█████████████████████████ 38.4%
| Telehealth Adoption Metric | Figure |
|---|---|
| Chlamydia tests completed via online postal self-sampling, 2015 | 2.6% |
| Chlamydia tests completed via online postal self-sampling, 2022 | 38.4% |
| Online consultations, 2019 vs. 2020 (pandemic effect) | 511,979 vs. 1,062,157 (doubled) |
| Chlamydia tests among 15-24-year-olds via online kits, 2010 vs. 2020 | 21% vs. 40% |
| Total sexual health screens, increase over a comparable multi-year period | 31% (1,657,425 to 2,175,525) |
Source: PMC-published retrospective cohort study, National Institute for Health and Care Research, 2025-2026; UCL Institute for Global Health ASSIST study, 2026.
Telehealth has fundamentally changed how STI testing happens in England over the past decade. The proportion of chlamydia testing completed through online postal self-sampling, where a person orders a free kit online, collects their own sample at home, and posts it to a lab, rose from just 2.6% of all tests in 2015 to 38.4% by 2022, according to a peer-reviewed cohort study funded by the National Institute for Health and Care Research. Among 15 to 24-year-olds, the age group with the highest STI rates, online kits grew from 21% of chlamydia tests in 2010 to 40% by 2020. The COVID-19 pandemic sharply accelerated that shift: online consultations for sexual health services doubled between 2019 and 2020 alone, jumping from 511,979 to 1,062,157, as clinic-based testing became harder to access.
That growth in online testing has translated directly into more testing overall, not just a shift in where existing tests happen. Total sexual health screens for chlamydia, gonorrhoea, syphilis, and HIV rose 31% over a comparable multi-year study period, from 1,657,425 to 2,175,525, a increase researchers attribute largely to online postal self-sampling making testing accessible to people who would otherwise have skipped it entirely, whether due to embarrassment, clinic waiting times, or simply not living near a sexual health service. Researchers studying this shift have also found real limits worth noting: uptake has been consistently lower among people in more deprived areas, meaning the convenience gains from telehealth have not reached everyone equally.
Online Postal Self-Sampling Statistics in the UK 2026
Online Postal Self-Sampling Testing Cascade
STI kit orders in three case study areas, 2022 |█████████████████████████ 610,876 orders
Kits returned (range across areas) |███████████████ 51.5%-78.4%
Returned kits with a valid sample |██████████████████████████████ 98.5%
| OPSS Cascade Metric | Figure |
|---|---|
| STI kit orders across three English case study areas, 2022 | 610,876 orders |
| Share of dispatched kits returned to the lab | 51.5% to 78.4% (varies by area) |
| Returned kits containing a valid, processable sample | 98.5% |
| Chlamydia positivity rate among kit orders | 3.7% to 5.7% (varies by area) |
| Users most likely to use online kits (demographic pattern) | Asymptomatic, white, women, over 20, less-deprived areas |
Source: SexTrans/BMJ Group retrospective observational study, 2025-2026.
A large 2025-2026 retrospective study covering three English case study areas gives the clearest picture yet of how the online postal self-sampling system actually performs in practice. Across the areas studied, 610,876 STI kit orders were placed and dispatched in a single year, and once a kit reached someone’s home, 51.5% to 78.4% of them were actually returned to a lab for testing, a completion rate that varied meaningfully by area and likely reflects differences in local reminder systems and population engagement. Of the kits that did come back, an encouraging 98.5% contained at least one valid, processable sample, meaning the self-collection process itself works reliably once someone follows through and posts their kit.
Chlamydia positivity among kit orders ranged from 3.7% to 5.7% depending on the area, broadly in line with rates seen in clinic-based testing, which suggests online kits are reaching a comparable risk population rather than just the worried-well. Researchers have consistently found that online kit users skew toward being asymptomatic, white, female, over 20, and from less deprived areas, a pattern that has held steady across multiple studies going back to the early rollout of these services. That consistent demographic skew is the central equity concern researchers keep flagging: online postal self-sampling has clearly expanded overall testing capacity, but it has done so by disproportionately serving people who already had the digital literacy, private postal address, and confidence to order a kit online in the first place.
STI Diagnosis Statistics in the UK 2026
STI Diagnoses in England, 2025 (Year-on-Year Change)
Infectious syphilis |▼ -13.5%
Gonorrhoea |▼ -10.9%
Chlamydia |▼ -10.3%
Genital warts (first episode) |▼ -7.3%
Genital herpes |▲ +3.1%
| STI Diagnosis Metric (2025, England) | Year-on-Year Change |
|---|---|
| Overall STI diagnoses | -8.3% |
| Infectious syphilis | -13.5% |
| Gonorrhoea | -10.9% |
| Chlamydia | -10.3% |
| First episode genital warts | -7.3% |
| Genital herpes | +3.1% |
Source: UK Health Security Agency, Sexually Transmitted Infections and Screening for Chlamydia in England: 2025 Report, published June 2026.
The UK Health Security Agency’s official 2025 data, published in June 2026, shows a broadly encouraging picture for England’s most common STIs. Overall diagnoses fell 8.3% compared with 2024, with the sharpest declines in infectious syphilis at -13.5%, gonorrhoea at -10.9%, and chlamydia, still the single most common STI, down 10.3% and accounting for 45.2% of every new STI diagnosis recorded in 2025. First episode genital warts continued a longer-running decline, falling 7.3%, a trend UKHSA links to the ongoing success of the school-based HPV vaccination programme. UKHSA specifically flagged the start of doxyPEP and the 4CMenB vaccine rollout at sexual health services between June and August 2025 as a possible contributing factor to the decline, though the agency was careful to note it is still too early to fully separate the impact of those interventions from other factors.
Not every trend moved in the same direction, and UKHSA was explicit about flagging the exception. Genital herpes diagnoses rose 3.1% even as most other infections fell, and while infectious syphilis declined overall, diagnoses specifically among heterosexual women actually rose 4.8% over the same period, a divergence UKHSA highlighted as a reason for continued caution rather than treating the year’s overall fall as an unambiguous success story. That combination, most infections falling while a smaller number of specific groups see diagnoses climb, is a pattern that recurs throughout the UK’s STI surveillance data and is exactly why public health officials continue to caution against reading a single top-line percentage as the whole picture.
STI Trends by Population Group Statistics in the UK 2026
STI Diagnosis Changes by Group, England, 2025 vs. 2024
GBMSM: infectious syphilis |▼ -18.7% (lowest since 2016)
GBMSM: chlamydia |▼ -14.4%
GBMSM: gonorrhoea |▼ -5.9%
Young people 15-24: overall STIs |▼ -12.5%
Heterosexual women: syphilis |▲ +4.8%
| Population Group Metric (2025 vs. 2024) | Change |
|---|---|
| GBMSM, infectious syphilis | -18.7% (lowest level since 2016) |
| GBMSM, chlamydia | -14.4% |
| GBMSM, gonorrhoea | -5.9% |
| Young people aged 15-24, overall STI diagnoses | -12.5% |
| Young people aged 15-24, gonorrhoea specifically | -21.5% |
| Heterosexual women, syphilis diagnoses | +4.8% |
Source: UK Health Security Agency, Sexually Transmitted Infections and Screening for Chlamydia in England: 2025 Report, published June 2026.
STI trends in England in 2025 varied sharply by population group, and UKHSA’s data shows some of the largest improvements occurred among gay, bisexual, and other men who have sex with men (GBMSM), a group that has historically carried some of the highest diagnosis rates in the country. Infectious syphilis among GBMSM fell 18.7%, reaching its lowest level since 2016, while chlamydia and gonorrhoea in the same group fell 14.4% and 5.9% respectively. Young people aged 15 to 24 also saw a substantial improvement, with overall STI diagnoses down 12.5% compared with 2024, driven by a particularly sharp 21.5% fall in gonorrhoea diagnoses within that age group.
Despite these gains, UKHSA’s report is explicit that STI diagnosis rates continue to be disproportionately high among GBMSM, young people aged 15 to 24, and people from some Black or Mixed ethnic groups, meaning the declines represent progress against a still-elevated baseline rather than the underlying inequality closing. The rise in syphilis diagnoses among heterosexual women, up 4.8% even as the overall syphilis trend improved, is the clearest example in this year’s data of a population moving in the opposite direction from the national average, and UKHSA researchers say it warrants continued monitoring rather than being dismissed as noise within an otherwise positive year.
NHS Sexual Health Service Funding Statistics in the UK 2026
Local Authority Sexual Health Service Spending, England (Real Terms)
2013/14 |██████████████████████████████████ £859 million
2024/25 |███████████████████████ £586 million
Real-terms decline: approximately one third
| Funding Metric | Figure |
|---|---|
| Local authority sexual health service spending, 2013/14 | £859 million (real terms) |
| Local authority sexual health service spending, 2024/25 | £586 million (real terms) |
| Real-terms decline over the period | Approximately one-third |
| Responsibility transferred from NHS to local authorities | 2013 |
| Total sexual health screens conducted, 2024 | 2,367,853 |
Source: House of Commons Library, Sexual Health Statistics for England, June 2026.
Behind the UK’s telehealth expansion and improving diagnosis figures sits a public health funding picture that has moved in the opposite direction. Responsibility for sexual health services transferred from the NHS to local authorities in 2013, and since then, spending on those services has fallen in real terms from £859 million in 2013/14 to £586 million in 2024/25, a decline of roughly a third once inflation is taken into account, according to the House of Commons Library’s most recent briefing. That funding squeeze has coincided with the period in which online postal self-sampling expanded from a niche offering to nearly 40% of chlamydia testing, and researchers studying the sector have drawn a direct link between the two trends: online testing has functioned as a way for stretched services to process rising testing demand without a matching increase in clinic staff or physical space.
Despite the funding pressure, the overall volume of testing has held roughly steady rather than collapsing, with 2,367,853 sexual health screens conducted in England in 2024, only slightly down from 2,380,498 the year before. That stability, achieved against a backdrop of falling real-terms funding, is largely attributable to the efficiency gains from shifting a growing share of testing online, though public health researchers and the NHS Workforce Statistics data both point to the same underlying concern: a service that has absorbed a decade of funding cuts through efficiency alone has little room left to absorb further pressure without either service quality or access beginning to suffer, particularly for the populations who cannot or do not use online testing.
Contraception and Family Planning Access Statistics in the UK 2026
| Contraception Access Metric | Status / Data |
|---|---|
| Primary UK data source for contraceptive service use | NHS Digital, Sexual and Reproductive Health (SRH) Services, England (Contraception), 2024/25 |
| Category most affected by sexual health funding pressure | Local authority-commissioned contraceptive and SRH services |
| Distribution shift for repeat contraceptive prescriptions | Increasing move to online/telehealth reordering and delivery |
| Comparable US contraceptive usage benchmark, lifetime use | 99% of sexually active women |
Source: NHS Digital, Sexual and Reproductive Health Services, England (Contraception), 2024/25; House of Commons Library, June 2026.
Contraceptive access in the UK sits within the same local-authority-commissioned system that funds STI testing, which means the funding pressures described above apply directly to family planning services too. NHS Digital’s annual Sexual and Reproductive Health Services report is the primary source tracking how many people access NHS-funded contraception each year, and it feeds directly into the same local government budgets that have seen the real-terms cuts detailed in the funding section above. As with STI testing, contraceptive access has increasingly moved toward online and telehealth channels, with repeat prescriptions for the contraceptive pill and other hormonal methods increasingly reordered through apps and online pharmacy platforms rather than in-person GP visits, mirroring the broader UK sexual wellness market’s shift toward digital-first, discreet service delivery.
For useful international context, comparable data from the Contraception Statistics in the U.S report shows that 99% of sexually active American women have used at least one contraceptive method in their lifetime, a figure that illustrates just how close to universal contraceptive use becomes once access barriers are removed, and offers a useful benchmark for UK policymakers assessing how much further domestic access could realistically improve. The core difference between the two systems is structural rather than cultural: US contraceptive access runs primarily through private insurance and individual purchasing decisions, while UK access runs through a public system currently absorbing a decade of local authority funding reductions, which shapes where the remaining access gaps are concentrated.
Online Pharmacy and Telehealth Prescription Statistics in the UK 2026
| Online Pharmacy Metric | Figure |
|---|---|
| Global online pharmacy distribution channel growth rate | ~16.8% CAGR (fastest-growing channel) |
| Primary driver of UK online pharmacy growth | Privacy, convenience, discreet delivery |
| Services now commonly bundled in one telehealth checkout | Consultation, prescription, and delivery |
| UK comparison point: general telehealth use growth | US telehealth utilization data available for benchmarking |
Source: Sexual Wellness Market Report, MarketDataForecast, 2026.
Online pharmacy has become the fastest-growing distribution channel in the broader sexual wellness market, expanding at roughly 16.8% annually according to industry market analysis, a pace driven almost entirely by demand for privacy and discreet delivery rather than price. In the UK specifically, this has translated into a now-familiar model where a person completes a short online consultation, is prescribed a treatment for something like erectile dysfunction, contraception, or an STI, and has it delivered to their door, all within a single digital checkout that never requires a face-to-face conversation with a pharmacist or GP unless a red flag is raised during the consultation.
This UK shift mirrors a broader pattern seen across other developed healthcare systems, and readers curious how far telehealth has spread beyond sexual health specifically can find a detailed breakdown in the Telehealth Statistics in US report, which documents how virtual care utilization across an entire healthcare system evolved from a niche pandemic-era tool into a permanent fixture of care delivery. The parallel is instructive: in both the UK and the US, sexual and behavioral health services have consistently been among the fastest and deepest adopters of telehealth models compared with other areas of medicine, largely because these consultations rarely require a physical examination and because patients specifically value the added privacy that a screen-based interaction provides over an in-person visit.
Sexual Health Testing Coverage and Screening Statistics in the UK 2026
Sexual Health Screening Volume, England
2023 |████████████████████████ 2,380,498 screens
2024 |██████████████████████ 2,367,853 screens
Change: roughly stable despite funding pressure
| Testing Coverage Metric | Figure |
|---|---|
| Total sexual health screens, England, 2023 | 2,380,498 |
| Total sexual health screens, England, 2024 | 2,367,853 |
| New interventions introduced, June-August 2025 | DoxyPEP, 4CMenB vaccine |
| UKHSA framework guiding local STI control prioritisation | STI Prioritisation Framework, published 2024 |
Source: UK Health Security Agency, Quarterly and Annual STI Surveillance Reports, 2025-2026.
Testing volume in England has stayed remarkably stable even as diagnosis numbers have shifted, with 2,367,853 sexual health screens for chlamydia, gonorrhoea, syphilis, and HIV recorded in 2024, only marginally down from 2,380,498 in 2023. That stability matters because it means the improving diagnosis figures detailed earlier in this report reflect a genuine change in infection rates rather than simply fewer people being tested, a distinction UKHSA is careful to draw out in its own reporting given how directly testing volume and diagnosis counts are linked.
Two newer clinical tools began rolling out at sexual health services between June and August 2025: doxyPEP, a post-exposure antibiotic approach aimed at reducing bacterial STI transmission, and the 4CMenB vaccine, offered specifically to reduce gonorrhoea risk in eligible groups. UKHSA’s own 2025 report is candid that it remains too early to fully attribute the year’s diagnosis declines to these two interventions specifically, since they were only active for the final third of the year covered by the data, but the agency has committed to further evaluation of their impact on both syphilis and gonorrhoea trends in future reporting cycles. UKHSA’s 2024 STI Prioritisation Framework now guides how local commissioners decide where to focus limited testing and outreach resources, an evidence-based triage approach that has become increasingly necessary as funding has tightened.
Future Outlook and Sexual Wellness Product Statistics in the UK 2026
UK Sexual Wellness Market: Where the Growth Is Concentrated
Online retail channel, Europe-wide 11.2% CAGR (2026-2034)
UK market overall 8.138% CAGR (2025-2035)
Bundled telehealth + product subscription models Emerging dominant model
| Future Trend Metric | Figure / Direction |
|---|---|
| UK sexual wellness market CAGR, 2025-2035 | 8.138% |
| European online retail channel CAGR, 2026-2034 | 11.2% |
| Dominant emerging business model | Bundled telehealth consultation + subscription product delivery |
| UK market position in Europe by 2035 | Projected to remain 2nd largest, behind Germany |
Source: MarketResearchFuture UK Sexual Wellness Market Report, 2026; Sexual Wellness Market Forecast, MarketResearchFuture, 2026.
Looking toward the rest of the decade, growth in the UK’s sexual wellness sector is expected to concentrate around two connected trends: continued migration to online retail, growing at 11.2% annually across Europe, and the rise of bundled telehealth-plus-product models, where a single subscription covers a recurring consultation, a prescription, and a physical product delivery in one relationship rather than three separate transactions. Industry analysts describe this as the shift from selling individual products to selling ongoing memberships, a model that has already taken hold in adjacent categories like skincare and is now spreading into contraception, ED treatment, and STI testing subscriptions in the UK market.
If current growth rates hold, the UK is projected to remain the second-largest sexual wellness market in Europe through 2035, trailing only Germany, with the market nearly tripling in value from its 2024 base. What will determine whether that growth translates into genuinely better public health outcomes, rather than just a larger commercial market sitting alongside a strained NHS system, is whether the efficiency gains from telehealth and online testing continue to be paired with the funding and outreach needed to reach the population groups, particularly those in deprived areas, who have consistently been the slowest to adopt online sexual health services throughout the past decade of data covered in this report.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
